This emphasises the need for predictive biomarkers and there is evidence suggesting a better response to treatment in patients whose tumours express PD-L1.6,11 However, clinical response has also occurred in patients with PD-L1 negative tumours and, conversely, PD-L1 expressing tumours have not responded to treatment. Here, CD274 is linked to neoplasm.